Process development of a New Haemophilus influenzae type b conjugate vaccine and the use of mathematical modeling to identify process optimization possibilities

Ahd Hamidi, Hans Kreeftenberg, Leo v.d. Pol, Saroj Ghimire, Luuk A M Luuk, Marcel Ottens

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Vaccination is one of the most successful public health interventions being a cost-effective tool in preventing deaths among young children. The earliest vaccines were developed following empirical methods, creating vaccines by trial and error. New process development tools, for example mathematical modeling, as well as new regulatory initiatives requiring better understanding of both the product and the process are being applied to well-characterized biopharmaceuticals (for example recombinant proteins). The vaccine industry is still running behind in comparison to these industries. A production process for a new Haemophilus influenzae type b (Hib) conjugate vaccine, including related quality control (QC) tests, was developed and transferred to a number of emerging vaccine manufacturers. This contributed to a sustainable global supply of affordable Hib conjugate vaccines, as illustrated by the market launch of the first Hib vaccine based on this technology in 2007 and concomitant price reduction of Hib vaccines. This paper describes the development approach followed for this Hib conjugate vaccine as well as the mathematical modeling tool applied recently in order to indicate options for further improvements of the initial Hib process. The strategy followed during the process development of this Hib conjugate vaccine was a targeted and integrated approach based on prior knowledge and experience with similar products using multi-disciplinary expertise. Mathematical modeling was used to develop a predictive model for the initial Hib process (the ‘baseline’ model) as well as an ‘optimized’ model, by proposing a number of process changes which could lead to further reduction in price.

Original languageEnglish
Pages (from-to)568-580
JournalBiotechnology Progress
Volume32
Issue number3
DOIs
Publication statusPublished - 1 May 2016

Keywords

  • conjugate
  • cost of goods
  • haemophilus influenzae type b vaccine
  • mathematical modeling
  • polysaccharide
  • process development
  • process optimization
  • PRP
  • targeted and integrated process development approach
  • technology transfer
  • unit operation

Fingerprint Dive into the research topics of 'Process development of a New Haemophilus influenzae type b conjugate vaccine and the use of mathematical modeling to identify process optimization possibilities'. Together they form a unique fingerprint.

  • Cite this